Fair pushback on regulatory complexity. The full Isubstrate analysis breaks down which therapeutic areas are moving fastest and why some companies are already banking 2-3 year time savings while others remain skeptical: https://finance.via.news/healthcare-investment/ai-virtual-twins-hit-2-000-medical-procedures-as-fda-guidelines-enable-drug. Plus the investment thesis for which device manufacturers are positioned to benefit first.